



Edition: BP 2025 (Ph. Eur. 11.6 update)

Metaraminol Injection

[General Notices](#)

Action and use

Adrenoceptor agonist.

DEFINITION

Metaraminol Injection is a sterile solution of Metaraminol Tartrate in Water for Injections.

The injection complies with the requirements stated under Parenteral Preparations and with the following requirements.

Content of metaraminol, $C_9H_{13}NO_2$

90.0 to 110.0% of the stated amount.

IDENTIFICATION

- A. In the test for Related substances, the principal spot in the chromatogram obtained with solution (2) corresponds to that in the chromatogram obtained with solution (5).
- B. Dilute a volume containing the equivalent of 5 mg of metaraminol to 10 mL with [water](#) and extract with four 15 mL quantities of [chloroform](#). To 0.5 mL of the aqueous layer add 0.5 mL of [phosphomolybdotungstic reagent](#) and 5 mL of [dilute sodium carbonate solution](#) and allow to stand for 5 minutes. An intense blue colour is produced.
- C. To 4 mL of the aqueous layer obtained in test B add 5 mL of [borate buffer pH 9.6](#) and 1 mL of a freshly prepared 0.5% w/v solution of [sodium 1,2-naphthoquinone-4-sulfonate](#) and allow to stand for 1 minute. Add 0.2 mL of a 2% v/v solution of [benzalkonium chloride solution](#) and 5 mL of [toluene](#) and shake. A mauve colour is produced immediately in the toluene layer (distinction from phenylephrine).

TESTS

Acidity

pH, 3.2 to 4.5, [Appendix V L](#).

Related substances

Carry out in subdued light the method for [thin-layer chromatography](#), [Appendix III A](#), using a silica gel precoated plate (Merck silica gel 60 plates are suitable) and a mixture of 10 volumes of 13.5M [ammonia](#), 80 volumes of [chloroform](#) and 80 volumes of [methanol](#) as the mobile phase. Apply separately to the plate 10 µL of each of the following solutions. For solution (1) evaporate a volume of the injection containing the equivalent of 20 mg of metaraminol to dryness, dissolve the residue as completely as possible in 2 mL of [methanol](#) and filter. For solution (2) dilute 1 volume of solution (1) to 20 volumes with [methanol](#). For solution (3) dilute 1 volume of solution (1) to 100 volumes with [methanol](#). Solution (4) contains 0.1% w/v of [methyl 4-hydroxybenzoate](#) in [methanol](#). Solution (5) contains 0.050% w/v of [metaraminol tartrate BPCRS](#) in [methanol](#). After removal of the plate, allow it to dry in air and spray with a solution prepared in the following manner. Mix

25 mL of a 0.45% w/v solution of [sulfanilic acid](#) in 1M [hydrochloric acid](#) with 1.5 mL of a 5% w/v solution of [sodium nitrite](#), allow to stand for 5 minutes and mix cautiously with 25 mL of 2M [sodium carbonate](#). Any [secondary spot](#) in the chromatogram obtained with solution (1), other than any spot corresponding to methyl 4-hydroxybenzoate, is not more intense than the spot in the chromatogram obtained with solution (3) (1%).

ASSAY

To a quantity containing the equivalent of 10 mg of metaraminol add sufficient [water](#) to produce 200 mL. Wash 25 mL with four 25 mL quantities of [chloroform](#), discard the washings and filter the aqueous solution. Measure the [absorbance](#) of the filtrate at the maximum at 272 nm, [Appendix II B](#). Calculate the content of $C_9H_{13}NO_2$ taking 111 as the value of A(1%, 1 cm) at the maximum at 272 nm.

STORAGE

Metaraminol Injection should be protected from light.

LABELLING

The strength is stated in terms of the equivalent amount of metaraminol in a suitable dose-volume.